ESMO 2026 floor digest: the trials shaping the congress agenda
Start here
At the ESMO 2026 congress in late October, attention concentrated on a set of practice-relevant trials presented on the floor. Among the most discussed were DELLPHI-305, VOLGA, INTERPATH-001, tarlatamab, durvalumab, FOURLIGHT-1, DASL-HICAP and POSTMONARCH. The floor digest ranks these by the weight of discussion they generated, with DELLPHI-305 and VOLGA drawing the heaviest interest, followed by INTERPATH-001 and studies of tarlatamab and durvalumab. The reports span several tumour types and treatment settings, from novel antibody-drug conjugates and bispecifics to immunotherapy regimens. Congress coverage is complete for this digest; what remains open is how these results translate into regulatory filings and clinical guidelines.
Written by a model from the reports
Coverage timeline
Follow the coverage to see the different angles.
- cba-usa.newsPickESMO 2026 · 10 2026-10-24 floor digest
1. DELLPHI-305 (53); 2. VOLGA (42); 3. INTERPATH-001 (33); 4. tarlatamab (21); 5. durvalumab (21); 6. FOURLIGHT-1 (19); 7. DASL-HICAP (17); 8. POSTMONARCH (16)
Heat trend for this story
Heat now 3·Peak in the comparable set 10 (Oct 25 12:00)·Change over 24h in the comparable set -49%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.